LXR, PPARγ, and PPARδ Agonists Are Not Sufficient to Demonstrate Therapeutic Potential against Mouse Model of Systemic Lupus Erythematosus

Noriko Toyota Tatebe, Katsue Sunahori Watanabe, Sonia Zeggar, Sumie Hiramatsu, Minglu Yan, Takayuki Katsuyama, Eri Katsuyama, Haruki Watanabe, Ken-ei Sada, Jun Wada*

Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Email: *junwada@okayama-u.ac.jp


Received: April 28, 2017
Accepted: May 28, 2017
Published: May 31, 2017

Copyright © 2017 by authors and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).
http://creativecommons.org/licenses/by/4.0/

Open Access

Abstract

Aim: We aimed to investigate whether the agonists for liver X receptor (LXR) ameliorate lupus-like phenotypes in mice mediated by the clearance of apoptotic cells, and compare with peroxisome proliferator-activated receptor (PPAR) γ plus PPARδ agonists, which also facilitate the clearance of apoptotic cells and exert anti-inflammatory effects in systemic lupus erythematosus (SLE). Methods: We investigated the efficacy of LXR agonist (GW3965) or dual treatment of PPAR γ (pioglitazone) and PPAR δ (GW0742) agonists in SLE animal models, female MRL/MpJ-Fas<lpr>/J mice and BALB/cAJcl mice treated with pristane. The data were analyzed with one-way analysis of variance and Tukey’s honestly significant difference tests. Results: The treatment with LXR or PPARγ/δ agonists did not significantly alter the swelling of lymph nodes, ds-DNA production, albuminuria, histological score of glomerular lesions, and mRNA expression of target genes including Abca1, C1qa, Icam1, Mertk and Tnf. Conclusion: LXR or PPARγ/δ agonists targeting the impaired clearance for apoptosis cells may not be efficient in the remission induction therapy in SLE.

Keywords

Nuclear Receptors, Liver X Receptor (LXR), Peroxisome Proliferator-Activated Receptor (PPAR), Systemic Lupus Erythematosus (SLE)

1. Introduction

Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease...
with systemic organ involvements and the current therapies are limited to sub-optimal treatments. Peroxisome proliferator-activated receptor \( \gamma \) (PPAR\( \gamma \)) agonists are widely prescribed for the pharmacological treatment of type 2 diabetes by their insulin-sensitizing properties. PPAR\( \gamma \) agonists also exert anti-inflammatory and immunomodulatory effects, and the beneficial impacts of rosiglitazone were reported for the amelioration of the autoantibody production, renal disease, and atherosclerosis in MRL-\( lpr \) mice depending on the induction of adiponectin [1] and also in NZBWF1 mice [2]. SLE is associated with increased circulating apoptotic autoantigens and increased type I interferon (IFN) signaling which simulate the production of autoantibody including anti-dsDNA antibodies [3]. Genetic depletion of PPAR\( \delta \) decreased the expression of opsonins such as C1qb and Mertk, which was resulted in the impairment of clearance for apoptotic cells and autoimmune kidney disease resembling lupus nephritis in human [4]. Engulfment of apoptotic cells by macrophages activated liver X receptor (LXR) and induced the transcriptional activation of Mertk. The lack of LXR also manifested the defects of self-tolerance and developed autoimmune glomerulonephritis [5]. Thus, the administration of PPAR\( \delta \) agonist or LXR agonist may be beneficial for the treatment of SLE by enhancing the clearance of apoptotic bodies. The efforts were made to develop the PPAR\( \gamma \)/\( \delta \) dual agonists without the deleterious side effects associated with full PPAR\( \gamma \) agonists such as weight gain, edema and osteoporosis [6] and simultaneous stimulation of both PPAR\( \gamma \) and PPAR\( \delta \) may be beneficial in the treatment of SLE. In the current investigation, we explored the efficacy of LXR agonist (GW3965) or dual treatment of PPAR\( \gamma \) (pioglitazone) and PPAR\( \delta \) (GW0742) agonists in SLE animal model in mice, female MRL/MpJ-Fas<\( lpr >/J \) mice and BALB/cAJcl mice treated with pristane.

2. Methods

2.1. Animal

Female MRL/MpJ-Fas<\( lpr >/J \) (MRL) mice at 8 weeks of age (Jackson) were used for animal experiments. The animals were divided into 3 groups, MRL/MpJ-Fas<\( lpr >/J \) mice (MRL; \( n = 10 \)), treated with 20 mg/kg/day of GW3965 (LXR; \( n = 8 \)), and treated with 25 mg/kg/day of pioglitazone and 1 mg/kg/day of GW0742 (PPAR\( \delta \); \( n = 9 \)) (Sigma-Aldrich) from 8 to 20 weeks of age. For preparation of stock solutions, 100 mg of GW3965, 125 mg of pioglitazone, and 5 mg of GW0742 were dissolved in 200 \( \mu \)g DMSO and mixed with 125 mg of hydroxyl methylcellulose. Water was added to total volume of 25 ml and they were kept in \(-20^\circ C\) for further use. Sera and urine samples were collected at 14 weeks of age, and they were sacrificed at 20 weeks of age and used for following experiments. Feeding needle was used for oral administration of agents for 3 times per week.

Female BALB/cAJcl mice (CLEA Japan) were injected with pristane at 10 weeks of age and they were divided into three groups, control (BALB/c; \( n = 10 \)), 20 mg/kg/day of GW3965 treated (LXR; \( n = 11 \)), and 25 mg/kg/day of pioglitaza-
zone plus 1 mg/kg/day of GW0742 treated (PPAR γ/δ; n = 10) (Sigma-Aldrich) groups from 11 to 23 weeks of age. Sera and urine samples were collected at 17 weeks of age, and they were sacrificed at 23 weeks of age and used for following experiments.

The methods were carried out in accordance with the approved guidelines. All experimental protocols were approved by the Animal Care and Use Committee of the Department of Animal Resources, Advanced Science Research Center, Okayama University.

2.2. Measurement of Urinary Albumin Excretion and dsDNA Antibodies

Urinary albumin excretions were measured with mouse albumin ELISA kit (Shibayagi, Japan) and standardized by the concentrations of urine creatinine. dsDNA antibodies were measured with mouse anti-dsDNA ELISA kit (Shibayagi, Japan).

2.3. Histopathology and Scoring

Kidney specimens were fixed with 10% buffered formalin and embedded in paraffin. Serial 2-μm sections were stained with periodic acid Schiff (PAS) for histological examination by light microscopy. Glomerular lesions were graded according to reported criteria: grade 0, no recognizable lesion in glomeruli; grade 1, mild cell proliferation and/or cell infiltration; grade 2, the same as grade 1 with mesangial proliferation, lobulation and hyaline droplet, associated with macrophage infiltration; grade 3, the same as grade 2 with crescent and granuloma formation and/or hyalinosis [7]. Glomeruli of more than 20 renal glomeruli examined in each mouse.

2.4. Real-Time RT-PCR

Kidney tissues were homogenized by Tissuelyser Adapter Set 2X24 (QIAGEN) with 1 ml QIAzolLysis Reagent (QIAGEN) and total RNAs extracted by RNeasy Lipid Tissue Mini Kit (QIAGEN). Then, 1 μg total RNAs were used to synthesize cDNA by using High Capacity RNA-to-cDNA Kit (Applied Biosystems). Quantitative real-time PCR was performed in Step One Plus Real-Time PCR System (Applied Biosystems) with specific primers and Universal Master Mix II (Life Technologies) and TaqMan Gene Expression Assays to evaluate the gene expression of intercellular adhesion molecule 1 (Mm00516023_m1), tumor necrosis factor (Mm00443258_m1), complement component 1, q subcomponent, alpha polypeptide (Mm00432142_m1), ATP-binding cassette, sub-family A (ABC1), member 1 (Mm00442646_m1), c-mer proto-oncogene tyrosine kinase (Mm00434920_m1). The relative abundance of mRNAs was standardized with GAPDH mRNA as the invariant control.

2.5. Statistical Analysis

Data are expressed as the mean ± standard error. The data were also analyzed
with one-way analysis of variance and Tukey’s honestly significant difference test when multiple comparisons against the control were required. P < 0.05 was regarded as statistically significant. Pearson’s χ² test was used to compare the distribution of glomeruli with grading scores from 0 to 3. The data were analyzed with JMP 8.0.2 software package (SAS Institute Inc.).

3. Results

3.1. Effects of LXR Agonist and PPARγ/δ Agonists in MRL Mice

MRL mice at 8 weeks of age were administered with LXR or dual treatment of PPARγ and PPARδ (PPARγ/δ) agonists for 12 weeks. There were no statistically significant differences in body, kidney and lymph node weights in PPARγ/δ and LXR groups compared with MRL group (Figures 1(a)-1(d)). In MRL group, urine albumin-to-creatinine ratio (UACR) progressively increased at 14 and 20 weeks of age. At 20 weeks of age, the treatments with LXR agonist or PPARγ/δ agonists demonstrated the reduction of UACR; however, it did not reach statistical differences (Figure 1(e)). The administration of PPARγ/δ agonists did not demonstrate therapeutic effects on the titer of anti-dsDNA antibodies. The titer of anti-dsDNA antibodies in LXR group was rather elevated and deteriorated compared with MRL mice with significant difference (p = 0.002) (Figure 1(f)).

We next performed the histopathological grading of glomerular lesions as previously described [7]. The treatments with PPARγ/δ and LXR agonists reduced the average scores of glomerular lesions but they were not statistically significant (Figure 2(a)). Furthermore, the distribution of glomeruli with grading scores from 0 to 3 was not significantly altered by the treatments with PPARγ/δ and LXR agonists (Figure 2(b) and Figure 2(c)). The genes such as Abca1, Clqα, and Mertk are under the transcriptional control of PPARγ, PPARδ, and LXR, respectively, in addition, the genes related to inflammation, Icam1 and Tnf, may be suppressed by PPARγ agonists. The mRNA expression of these genes were reduced in PPARγ/δ and LXR groups compared with MRL mice, but they were not statistically significant again (Figure 2(d)). Taken together, the administration of LXR or PPARγ/δ agonists into MRL mice demonstrated the tendency to ameliorate the albuminuria and histological scores in MRL mice; however, it did not exhibit sufficient therapeutic potential against glomerulonephritis in MRL mice.

3.2. Effects of LXR Agonist and PPARγ/δ Agonists in Pristane-Treated BALB/cAJcl Mice

Female MRL mice demonstrate the “severe” disease phenotype with an average lifespan of 17 weeks and we further tested the preventive effects of PPARγ/δ and LXR agonists in pristane-treated BALB/cAJcl (BALB/c) mice with milder phenotype of lupus and glomerulonephritis. There were no statistically significant differences in body, kidney and lymph node weights in PPARγ/δ and LXR groups compared with BALB/c mice treated with pristane (Figure 3(a) and Figure 3(b)). The administration of PPARγ/δ and LXR agonists did not alter the
Figure 1. The administration of LXR agonist (GW3965) (LXR) or dual treatment of PPARγ (pioglitazone) and PPARδ (GW0742) agonists (PPARγ/δ) in MRL/MpJ-Fas<sup>−/−</sup> (MRL) mice. (a) Lymph nodes weight, (b) Lymph nodes/body weight, (c) Kidney weight, (d) Kidney/body weight, (e) Urine albumin/creatinine, (f) Anti-dsDNA antibody. ns, not significant.

4. Discussion

In the current investigation, LXR or dual treatment of PPARγ/δ agonists demonstrated only minimal beneficial effects in the treatment of established and severe autoimmune phenotypes in MRL mice. We also tested the efficacy of LXR urinary excretion of albumin (Figure 3(c)). The glomeruli in BALB/c mice treated with pristane demonstrated mild proliferation of glomerular cells but there were no differences in PPARγ/δ and LXR groups compared with BALB/c mice with pristane.
or PPARγ/δ agonists in BALB/c mice treated with pristane with mild autoimmune phenotypes and again it demonstrated the minimal therapeutic potential. Recent work suggested that PPARγ agonist treatment started before disease onset demonstrated the marked amelioration of disease, while it was not effective when started after disease onset [8]. We thought that the administration of LXR or PPARγ/δ agonists at 8 weeks of age might be too late to suppress the disease and we administered them immediately after the injection of pristane in BALB/c mice; however, they did not reveal the beneficial effects in prevention. The interventions to enhance the clearance of apoptotic body may not be sufficient to suppress the autoimmune phenotypes in SLE. In addition, PPARγ agonist is known to be beneficial to ameliorate the chronic or subclinical inflammation; however, it may not be effective to suppress the acute and severe inflammatory

**Figure 2.** Histology scoring and RT-PCR in MRL/MpJ-Fas<sup>-/-</sup>/J (MRL) mice and mice treated with LXR agonist (GW3965) (LXR) or dual treatment of PPARγ (pioglitazone) and PPARδ (GW0742) agonists (PPARγ/δ). (a) Average score, (b) Score distribution, (c) PAS stain of kidney tissues, (d) Quantitative RT-PCR. ns, not significant.
Figure 3. The administration of LXR agonist (GW3965) (LXR) or dual treatment of PPARγ (pioglitazone) and PPARδ (GW0742) agonists (PPARγ/δ) in BALB/cAJcl mice treated with pristane. (a) Kidney weight, (b) Kidney/body weight, (c) Urine albumin/creatinine, (d) PAS stain of kidney tissues. ns, not significant.

response in SLE. In gld. apoE (−/−) with accelerated atherosclerosis and SLE, PPARγ agonist demonstrated the marked amelioration in atherosclerosis and minimal impacts on autoimmune phenotype such as autoantibody production [8].

The ineffectiveness of LXR or PPARγ/δ agonists in lupus animal models was also explained by the unfavorable changes in global gene expression profiles or alterations in endogenous lipid ligands. The stimulation of nuclear receptors may induce both favorable and unwanted changes in mRNA expression profile, although we did not perform the profiling such as DNA microarray. In addition, PPARγ and LXR bind to various physiological lipid ligands such as unsaturated fatty acids and hydroxylcholesterol, respectively [9], and the alterations of such lipid ligands also influence the activation of nuclear receptors.

The limitation of current study is that we did not investigate the dose-effect relationship and the higher doses may exert the beneficial effects on SLE, although we employed the doses which were used in previous studies. Second, we
did not investigate the simultaneous use of steroids or immune suppressants with LXR or PPARγ/δ agonists, which might be beneficial in the treatment of SLE. Finally, the results in SLE animal models in mice may not be applicable to human and the clinical studies have not been performed since LXR and PPARδ agonists have not been approved so far in the market.

5. Conclusion

The use of nuclear receptor agonists such as LXR or PPARγ/δ agonists seems to be not effective in the treatment of MRL and pristane-treated BALB/c mice. Efficacy of LXR or PPARγ/δ agonists may be tested in the patients with SLE in combination with steroids and immune suppressants.

Competing Interests

The authors declare to have no competing interests.

Funding

This work was supported by JSPS Grant-in-Aid for Scientific Research, Grant Numbers (25126716, 26293218).

Author’s Contributions

Study concept: NTT, KSW, KS and JW. Animal experiments: NTT, SZ, SH, TK, and EK. RT-PCR: SH and MY. Statistical analysis: NTT and JW. Manuscript writing: NTT, KSW and JW. All authors approved the final manuscript.

References


**Abbreviations**

- ELISA: enzyme-linked immunosorbent assay.
- GAPDH: glyceraldehyde-3-phosphate dehydrogenase.
- PPAR: peroxisome proliferator-activated receptor.
- SLE: systemic lupus erythematosus.
- LXR: liver X receptor.

---

Submit or recommend next manuscript to SCIRP and we will provide best service for you:

Accepting pre-submission inquiries through Email, Facebook, LinkedIn, Twitter, etc.
A wide selection of journals (inclusive of 9 subjects, more than 200 journals)
Providing 24-hour high-quality service
User-friendly online submission system
Fair and swift peer-review system
Efficient typesetting and proofreading procedure
Display of the result of downloads and visits, as well as the number of cited articles
Maximum dissemination of your research work

Submit your manuscript at: [http://papersubmission.scirp.org/](http://papersubmission.scirp.org/)
Or contact ojra@scirp.org